mor106
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02739009)
Timeline
Indications
Mechanism of action
- Interleukin-17CINHIBITOR
IL17C inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mor106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03864627 | Phase 2 | Mar 25, 2019 | Galapagos NV |
| NCT03689829 | Phase 1 | Aug 13, 2018 | Galapagos NV |
| NCT03568071 | Phase 2 | Apr 26, 2018 | Galapagos NV |
| NCT02739009 | Phase 1 | Apr 1, 2016 | Galapagos NV, MorphoSys |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 4 | 4 | 2 | 2016 |
| MorphoSys | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1